NAP (Davunetide)
Overview
NAP, also known as davunetide, is an eight-amino acid peptide derived from activity-dependent neuroprotective protein (ADNP). It is thought to stabilize microtubules by interacting with tubulin and promoting cytoskeletal integrity, thereby protecting neurons from oxidative stress, excitotoxicity, and tauopathies.
Mechanism of Action
Intranasal delivery was pursued to achieve direct central nervous system access while minimizing systemic exposure.
Research Summary & Key Findings
Phase II trials in amnestic mild cognitive impairment and progressive supranuclear palsy were completed, but davunetide failed to meet primary cognitive or functional endpoints. A phase II/III trial in progressive supranuclear palsy was terminated early due to lack of efficacy, as reported in presentations at international conferences around 2012.
Clinical Status
NAP (Davunetide) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed — "NAP"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "NAP"
Registered interventional and observational studies, including status and phase.
- PubChem — "NAP"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Cognitive
Semax
FDA ApprovedA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotecti...
View detailsSelank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stabi...
View detailsCerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that m...
View detailsP21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neuro...
View detailsStart Your Consultation
Get an AI-proposed NAP (Davunetide) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply NAP (Davunetide).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.